Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
暂无分享,去创建一个
R. Uchi | M. Masuda | R. Yasumatsu | T. Nakagawa | T. Wakasaki | Rina Jiromaru | K. Hashimoto | M. Matsuo | Tomomi Manako | T. Takeuchi